St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
2000/06/13 by Linda B. Moore, Bryan Goodwin, Stacey A. Jones +6 · 35 citations
Pharmacology, Toxicology and Pharmaceutics · Medicine · #Pharmacogenetics and Drug Metabolism #Pharmacological Effects and Toxicity Studies #Drug Transport and Resistance Mechanisms
paper · doi:10.1073/pnas.130155097
Abstract
St. John's wort (Hypericum perforatum) is an herbal remedy used widely for the treatment of depression. Recent clinical studies demonstrate that hypericum extracts increase the metabolism of various drugs, including combined oral contraceptives, cyclosporin, and indinavir. In this report, we show that hyperforin, a constituent of St. John's wort with antidepressant activity, is a potent ligand (K(i) = 27 nM) for the pregnane X receptor, an orphan nuclear receptor that regulates expression of the cytochrome P450 (CYP) 3A4 monooxygenase. Treatment of primary human hepatocytes with hypericum extracts or hyperforin results in a marked induction of CYP3A4 expression. Because CYP3A4 is involved in the oxidative metabolism of >50% of all drugs, our findings provide a molecular mechanism for the interaction of St. John's wort with drugs and suggest that hypericum extracts are likely to interact with many more drugs than previously had been realized.
Cited by
- St. John’s Wort Formulations Induce Rat CYP3A23-3A1 Independent of Their Hyperforin Content
- Hyperforin-Induced Activation of the Pregnane X Receptor Is Influenced by the Organic Anion-Transporting Polypeptide 2B1
- The enabling power of chemical probes: examples from the nuclear hormone receptor field
- Role of P-Glycoprotein in Pharmacokinetics
- Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
- The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel
- Dietary Modulation of CYP3A4 and Its Impact on Statins and Antidiabetic Drugs: A Narrative Review
- PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA
- Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes
- Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort
- Role of hyperforin in the pharmacological activities of St. John's Wort. [europepmc]
- In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. [europepmc]
- Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. [europepmc]
- Cytochrome P450 and xenobiotic receptor humanized mice. [europepmc]
- Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. [europepmc]
- Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. [europepmc]
- The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. [europepmc]
- Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. [europepmc]
- The pregnane X receptor: from bench to bedside. [europepmc]
- PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. [europepmc]
- The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. [europepmc]
- Improving the oral bioavailability of beneficial polyphenols through designed synergies. [europepmc]
- Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. [europepmc]
- Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation. [europepmc]
- Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. [europepmc]
- Nuclear receptor PXR, transcriptional circuits and metabolic relevance. [europepmc]
- FXR and PXR: potential therapeutic targets in cholestasis. [europepmc]
- Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. [europepmc]
- Cancer chemoprevention by carotenoids. [europepmc]
- Targeting xenobiotic receptors PXR and CAR for metabolic diseases. [europepmc]
- Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions. [europepmc]
- Gut microbial metabolites in depression: understanding the biochemical mechanisms. [europepmc]
- Clinical relevance of St. John's wort drug interactions revisited. [europepmc]
- A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. [europepmc]
- Depression and Its Phytopharmacotherapy-A Narrative Review. [europepmc]
Related